Find a Clinical Trial
Breast Cancer
Clinical Trial at: Texas Oncology - Paris
STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)
- Details
ClinicalTrials.gov ID:
NCT03975647
Diagnosis Type:
NA
USOR Number:
19054
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Urothelial Cancer
Clinical Trial at: Texas Oncology - Paris
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
- Details
ClinicalTrials.gov ID:
NCT03390504
Diagnosis Type:
NA
USOR Number:
17133
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Biliary Cancer
Clinical Trial at: Texas Oncology - Paris
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
- Details
ClinicalTrials.gov ID:
NCT03773302
Diagnosis Type:
NA
USOR Number:
18264
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Solid Tumors
Clinical Trial at: Texas Oncology - Paris
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- Details
ClinicalTrials.gov ID:
NCT03822117
Diagnosis Type:
NA
USOR Number:
19079
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Lung Cancer
Clinical Trial at: Texas Oncology - Paris
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
- Details
ClinicalTrials.gov ID:
NCT03515837
Diagnosis Type:
NA
USOR Number:
19020
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Lymphomas
Clinical Trial at: Texas Oncology - Paris
(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
- Details
ClinicalTrials.gov ID:
NCT01716806
Diagnosis Type:
Hodgkins
USOR Number:
11282
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Bladder Cancer
Clinical Trial at: Texas Oncology - Paris
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
- Details
ClinicalTrials.gov ID:
NCT03219333
Diagnosis Type:
NA
USOR Number:
17005
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Urothelial Cancer
Clinical Trial at: Texas Oncology - Paris
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
- Details
ClinicalTrials.gov ID:
NCT03219333
Diagnosis Type:
NA
USOR Number:
17005
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Prostate Cancer
Clinical Trial at: Texas Oncology - Paris
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
- Details
ClinicalTrials.gov ID:
NCT03706365
Diagnosis Type:
NA
USOR Number:
18128
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Lung Cancer
Clinical Trial at: Texas Oncology - Paris
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
- Details
ClinicalTrials.gov ID:
NCT03596866
Diagnosis Type:
NA
USOR Number:
18129
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Myelofibrosis
Clinical Trial at: Texas Oncology - Paris
INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
- Details
ClinicalTrials.gov ID:
NCT03144687
Diagnosis Type:
NA
USOR Number:
17085
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Prostate Cancer
Clinical Trial at: Texas Oncology - Paris
TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)
- Details
ClinicalTrials.gov ID:
NCT02975934
Diagnosis Type:
NA
USOR Number:
16238
- Practice Details
3550 N E Loop 286
Paris, Texas 75460
236.58 mi. away
P: (903) 785-0031
Lung Cancer
Clinical Trial at: Texas Oncology - Sherman
D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
- Details
ClinicalTrials.gov ID:
NCT03833154
Diagnosis Type:
NSCLC
USOR Number:
19044
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Bladder Cancer
Clinical Trial at: Texas Oncology - Sherman
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
- Details
ClinicalTrials.gov ID:
NCT03955913
Diagnosis Type:
NA
USOR Number:
19032
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Urothelial Cancer
Clinical Trial at: Texas Oncology - Sherman
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
- Details
ClinicalTrials.gov ID:
NCT03955913
Diagnosis Type:
NA
USOR Number:
19032
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Breast Cancer
Clinical Trial at: Texas Oncology - Sherman
STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)
- Details
ClinicalTrials.gov ID:
NCT03975647
Diagnosis Type:
NA
USOR Number:
19054
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Urothelial Cancer
Clinical Trial at: Texas Oncology - Sherman
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
- Details
ClinicalTrials.gov ID:
NCT03390504
Diagnosis Type:
NA
USOR Number:
17133
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Rectal Cancer
Clinical Trial at: Texas Oncology - Sherman
An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)
- Details
ClinicalTrials.gov ID:
NCT04126733
Diagnosis Type:
NA
USOR Number:
19096
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Colon Cancer
Clinical Trial at: Texas Oncology - Sherman
An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)
- Details
ClinicalTrials.gov ID:
NCT04126733
Diagnosis Type:
NA
USOR Number:
19096
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700
Biliary Cancer
Clinical Trial at: Texas Oncology - Sherman
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
- Details
ClinicalTrials.gov ID:
NCT03773302
Diagnosis Type:
NA
USOR Number:
18264
- Practice Details
2800 Highway 75 North
Sherman, Texas 75090
241.81 mi. away
P: (903) 868-4700